[Standard-of-care Systemic Therapy with or Without SBRT in Patients with Oligoprogressive Breast Cancer or NSCLC (CURB Oligoprogression): an Open-Label, Randomised, Controlled, Phase 2 Study].
STRAHLENTHERAPIE UND ONKOLOGIE（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined